Mallinckrodt plc to Report Third Quarter 2025 Financial Results on November 10, 2025

Rhea-AI Summary

Mallinckrodt (NYSE:MNK) will report its third quarter 2025 financial results on Monday, November 10, 2025 before market open.

The company will host a conference call the same day at 8:00 a.m. ET with an audio webcast available in the Investor Relations section at ir.mallinckrodt.com under Events & Presentations. Participants can register to receive a dial-in number and personalized PIN; attendees are advised to join 10 minutes early. A replay of the webcast will be available after the event.

DUBLIN, Oct. 23, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, announced today that it will report its third quarter 2025 financial results on Monday, November 10, 2025, before market open. The Company will host a conference call on the same day at 8:00 a.m. ET.

The audio webcast may be accessed through the Investor Relations section of the Company's website at ir.mallinckrodt.com under Events & Presentations through this webcast link. To access the call through a conference line, participants can register here to receive a dial-in number and personalized PIN to participate in the call. Participants are advised to join 10 minutes prior to the scheduled start time. A replay of the webcast will be available following the event.

ABOUT MALLINCKRODT
Mallinckrodt is dedicated to enhancing lives by providing therapeutics that strive to address unmet patient needs, and is a world-class manufacturer of high-quality generics, sterile injectables, and active pharmaceutical ingredients.

Our company consists of multiple wholly owned subsidiaries that operate in two businesses. Our Brands business is focused on autoimmune and rare diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients. To learn more, visit www.MNK-Endo.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Contacts

Investors 
Juan Avendano
avendano.juan@endo.com

Media 
Linda Huss
huss.linda@endo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-third-quarter-2025-financial-results-on-november-10-2025-302592122.html

SOURCE Mallinckrodt plc

FAQ

When will Mallinckrodt (MNK) report Q3 2025 results?

Mallinckrodt will report Q3 2025 results on Monday, November 10, 2025 before market open.

What time is the Mallinckrodt (MNK) Q3 2025 conference call?

The conference call is scheduled for 8:00 a.m. ET on November 10, 2025.

How can investors access the Mallinckrodt (MNK) Q3 2025 webcast?

The audio webcast will be available via the Investor Relations site at ir.mallinckrodt.com under Events & Presentations.

Do I need to register to join the Mallinckrodt (MNK) conference call by phone?

Yes. Register to receive a dial-in number and a personalized PIN to access the conference line.

Will there be a replay of the Mallinckrodt (MNK) Q3 2025 webcast?

Yes. A replay of the webcast will be available following the event on the Investor Relations site.